| 1 |
Designing anti-diabetic -cells microcapsules using polystyrenic sulfonate, polyallylamine, and a tertiary bile acid: Morphology, bioenergetics, and cytokine analysis
Mooranian A, Negrulj R, Al-Salami H, Morahan G, Jamieson E
Biotechnology Progress, 32(2), 501, 2016 |
| 2 |
The impact of allylamine-bile acid combinations on cell delivery microcapsules in diabetes
Mooranian A, Negrulj R, Al-Salami H
Journal of Microencapsulation, 33(6), 569, 2016 |
| 3 |
Release and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatment
Mooranian A, Negrulj R, Al-Sallami HS, Fang ZX, Mikov M, Golocorbin-Kon S, Fakhoury M, Arfuso F, Al-Salami H
Journal of Microencapsulation, 32(2), 151, 2015 |
| 4 |
Novel chenodeoxycholic acid-sodium alginate matrix in the microencapsulation of the potential antidiabetic drug, probucol. An in vitro study
Mooranian A, Negrulj R, Mikov M, Golocorbin-Kon S, Arfuso F, Al-Salami H
Journal of Microencapsulation, 32(6), 589, 2015 |
| 5 |
Release and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatment (vol 32, pg 151, 2014)
Mooranian A, Negrulj R, Al-Sallami HS, Fang Z, Mikov M, Golocorbin-Kon S, Fakhoury M, Arfuso F, Al-Salami S
Journal of Microencapsulation, 32(7), I, 2015 |
